Chemotherapy of advanced ovarian adenocarcinoma: A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin

H. J. Solomon; M. H N Tattersall; J. J. Campbell; K. Free; D. Humphrey; A. McCartney; G. McLeish; J. Skipper; A. S. Coates; D. R. McNeil; C. Sutherland; C. Swanson; D. Fortune

doi:10.1016/0090-8258(86)90109-5

Chemotherapy of advanced ovarian adenocarcinoma: A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin

H. J. Solomon, M. H N Tattersall^*, J. J. Campbell, K. Free, D. Humphrey, A. McCartney, G. McLeish, J. Skipper, A. S. Coates, D. R. McNeil, C. Sutherland, C. Swanson, D. Fortune

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Three hundred and sixty-nine patients with advanced ovarian adenocarcinoma were treated in a prospective randomized trial comparing combination versus sequential therapy with chlorambucil and cisplatin. Initial tumor response rates were similar but combination chemotherapy was associated with significantly prolonged time to first disease progression (median 28 weeks for chlorambucil and 42 weeks for combination chemotherapy). Secondline treatment with cisplatin in patients failing initial chlorambucil caused tumor response in 16.9%. Overall time to ultimate disease progression was similar between the treatment groups. The surgically documented complete response rate (second-look surgery at ≅12 months) and the survival was similar in the two treatment arms. Multivariate analysis of prognostic factors for survival in this trial showed that bulk of residual disease at time of starting therapy and the development of myelosuppression during therapy were the most important.

Original language	English
Pages (from-to)	1-13
Number of pages	13
Journal	Gynecologic Oncology
Volume	23
Issue number	1
DOIs	https://doi.org/10.1016/0090-8258(86)90109-5
Publication status	Published - 1986
Externally published	Yes

Access to Document

10.1016/0090-8258(86)90109-5

Cite this

Solomon, H. J., Tattersall, M. H. N., Campbell, J. J., Free, K., Humphrey, D., McCartney, A., McLeish, G., Skipper, J., Coates, A. S., McNeil, D. R., Sutherland, C., Swanson, C., & Fortune, D. (1986). Chemotherapy of advanced ovarian adenocarcinoma: A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin. Gynecologic Oncology, 23(1), 1-13. https://doi.org/10.1016/0090-8258(86)90109-5

@article{201dca4f37934d7ea7376f1c3b80afcf,

title = "Chemotherapy of advanced ovarian adenocarcinoma: A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin",

abstract = "Three hundred and sixty-nine patients with advanced ovarian adenocarcinoma were treated in a prospective randomized trial comparing combination versus sequential therapy with chlorambucil and cisplatin. Initial tumor response rates were similar but combination chemotherapy was associated with significantly prolonged time to first disease progression (median 28 weeks for chlorambucil and 42 weeks for combination chemotherapy). Secondline treatment with cisplatin in patients failing initial chlorambucil caused tumor response in 16.9%. Overall time to ultimate disease progression was similar between the treatment groups. The surgically documented complete response rate (second-look surgery at ≅12 months) and the survival was similar in the two treatment arms. Multivariate analysis of prognostic factors for survival in this trial showed that bulk of residual disease at time of starting therapy and the development of myelosuppression during therapy were the most important.",

author = "Solomon, {H. J.} and Tattersall, {M. H N} and Campbell, {J. J.} and K. Free and D. Humphrey and A. McCartney and G. McLeish and J. Skipper and Coates, {A. S.} and McNeil, {D. R.} and C. Sutherland and C. Swanson and D. Fortune",

year = "1986",

doi = "10.1016/0090-8258(86)90109-5",

language = "English",

volume = "23",

pages = "1--13",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

Solomon, HJ, Tattersall, MHN, Campbell, JJ, Free, K, Humphrey, D, McCartney, A, McLeish, G, Skipper, J, Coates, AS, McNeil, DR, Sutherland, C, Swanson, C & Fortune, D 1986, 'Chemotherapy of advanced ovarian adenocarcinoma: A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin', Gynecologic Oncology, vol. 23, no. 1, pp. 1-13. https://doi.org/10.1016/0090-8258(86)90109-5

TY - JOUR

T1 - Chemotherapy of advanced ovarian adenocarcinoma

T2 - A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin

AU - Solomon, H. J.

AU - Tattersall, M. H N

AU - Campbell, J. J.

AU - Free, K.

AU - Humphrey, D.

AU - McCartney, A.

AU - McLeish, G.

AU - Skipper, J.

AU - Coates, A. S.

AU - McNeil, D. R.

AU - Sutherland, C.

AU - Swanson, C.

AU - Fortune, D.

PY - 1986

Y1 - 1986

N2 - Three hundred and sixty-nine patients with advanced ovarian adenocarcinoma were treated in a prospective randomized trial comparing combination versus sequential therapy with chlorambucil and cisplatin. Initial tumor response rates were similar but combination chemotherapy was associated with significantly prolonged time to first disease progression (median 28 weeks for chlorambucil and 42 weeks for combination chemotherapy). Secondline treatment with cisplatin in patients failing initial chlorambucil caused tumor response in 16.9%. Overall time to ultimate disease progression was similar between the treatment groups. The surgically documented complete response rate (second-look surgery at ≅12 months) and the survival was similar in the two treatment arms. Multivariate analysis of prognostic factors for survival in this trial showed that bulk of residual disease at time of starting therapy and the development of myelosuppression during therapy were the most important.

AB - Three hundred and sixty-nine patients with advanced ovarian adenocarcinoma were treated in a prospective randomized trial comparing combination versus sequential therapy with chlorambucil and cisplatin. Initial tumor response rates were similar but combination chemotherapy was associated with significantly prolonged time to first disease progression (median 28 weeks for chlorambucil and 42 weeks for combination chemotherapy). Secondline treatment with cisplatin in patients failing initial chlorambucil caused tumor response in 16.9%. Overall time to ultimate disease progression was similar between the treatment groups. The surgically documented complete response rate (second-look surgery at ≅12 months) and the survival was similar in the two treatment arms. Multivariate analysis of prognostic factors for survival in this trial showed that bulk of residual disease at time of starting therapy and the development of myelosuppression during therapy were the most important.

UR - http://www.scopus.com/inward/record.url?scp=0022617373&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(86)90109-5

DO - 10.1016/0090-8258(86)90109-5

M3 - Article

C2 - 3510944

AN - SCOPUS:0022617373

VL - 23

SP - 1

EP - 13

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -

Chemotherapy of advanced ovarian adenocarcinoma: A randomized comparison of combination versus sequential therapy using chlorambucil and cisplatin

Abstract

Access to Document

Other files and links

Fingerprint

Cite this